Dmitriy Sonkin

Dr. Dmitriy Sonkin

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2012 in Nature
Verified
Journal Article
Open access
PDF file
JBJordi Barretina
Jordi Barretina
GCGiordano Caponigro
Giordano Caponigro
NSNicolas Stransky
Nicolas Stransky
KVKavitha Venkatesan
Kavitha Venkatesan
AMAdam A. Margolin
Adam A. Margolin
LGLevi A. Garraway
Levi A. Garraway
The Cancer Cell Line Encyclopedia presents the first results from a large-scale screen of some 947 cancer cell lines with 24 anticancer drugs, with the aim of identifying specific genomic alterations and gene expression profiles associated with selective sensitivity or resistance to potential therapeutic agents. Cancer cell lines are widely used as preclinical models to gain mechanistic and therapeutic insight. Two manuscripts in this issue describe the large-scale genetic and pharmacological characterization of human cancer cell lines. Each group characterized collections of several-hundred cell lines using different platforms and analytical methods. Their results are complementary, and confirm that many human cell lines capture the genomic diversity of their respective cancers. Initial findings include the identification of a number of potential markers of drug sensitivity and resistance. For example, Garnett et al. report an association between EWS-FLI1 gene translocations, frequently found in Ewing's sarcoma, and sensitivity to PARP inhibitors, a class of drug currently in clinical trials for other cancer types. Barretina et al. report a possible association between SLFN11 expression and sensitivity to topoisomerase inhibitors. The systematic translation of cancer genomic data into knowledge of tumour biology and therapeutic possibilities remains challenging. Such efforts should be greatly aided by robust preclinical model systems that reflect the genomic diversity of human cancers and for which detailed genetic and pharmacological annotation is available1. Here we describe the Cancer Cell Line Encyclopedia (CCLE): a compilation of gene expression, chromosomal copy number and massively parallel sequencing data from 947 human cancer cell lines. When coupled with pharmacological profiles for 24 anticancer drugs across 479 of the cell lines, this collection allowed identification of genetic, lineage, and gene-expression-based predictors of drug sensitivity. In addition to known predictors, we found that plasma cell lineage correlated with sensitivity to IGF1 receptor inhibitors; AHR expression was associated with MEK inhibitor efficacy in NRAS-mutant lines; and SLFN11 expression predicted sensitivity to topoisomerase inhibitors. Together, our results indicate that large, annotated cell-line collections may help to enable preclinical stratification schemata for anticancer agents. The generation of genetic predictions of drug response in the preclinical setting and their incorporation into cancer clinical trial design could speed the emergence of ‘personalized’ therapeutic regimens2.

8 May 2019 in Nature
Verified
Journal Article
Closed access
PDF file
MGMahmoud Ghandi
Mahmoud Ghandi
FHFranklin W. Huang
Franklin W. Huang
JJJudit Jané-Valbuena
Judit Jané-Valbuena
GKGregory V. Kryukov
Gregory V. Kryukov
CLChristopher C. Lo
Christopher C. Lo
WSWilliam R. Sellers
William R. Sellers

22 June 2016 in Human Mutation
Verified
Journal Article
Closed access
PDF file
LBLiacine Bouaoun
Liacine Bouaoun
DSDmitriy Sonkin
Dmitriy Sonkin
MAMaude Ardin
Maude Ardin
MHMonica Hollstein
Monica Hollstein
GBGraham Byrnes
Graham Byrnes
MOMagali Olivier
Magali Olivier

17 June 2024 in Cancer Genetics
Verified
Journal Article
Closed access
DSDmitriy Sonkin
Dmitriy Sonkin
ATAnish Thomas
Anish Thomas
BTBeverly A. Teicher
Beverly A. Teicher

29 January 2022 in Genetics in Medicine
Verified
Journal Article
Closed access
PHPeter Horak
Peter Horak
MGMalachi Griffith
Malachi Griffith
ADArpad M. Danos
Arpad M. Danos
BPBeth A. Pitel
Beth A. Pitel
SMSubha Madhavan
Subha Madhavan
DSDmitriy Sonkin
Dmitriy Sonkin

3 April 2020 in Nature Genetics
Verified
Journal Article
Open access
PDF file
VCVariant Interpretation for Cancer Consortium
Variant Interpretation for Cancer Consortium
AWAlex H. Wagner
Alex H. Wagner
BWBrian Walsh
Brian Walsh
GMGeorgia Mayfield
Georgia Mayfield
DTDavid Tamborero
David Tamborero
AMAdam A. Margolin
Adam A. Margolin
Precision oncology relies on accurate discovery and interpretation of genomic variants, enabling individualized diagnosis, prognosis and therapy selection. We found that six prominent somatic cancer variant knowledgebases were highly disparate in content, structure and supporting primary literature, impeding consensus when evaluating variants and their relevance in a clinical setting. We developed a framework for harmonizing variant interpretations to produce a meta-knowledgebase of 12,856 aggregate interpretations. We demonstrated large gains in overlap between resources across variants, diseases and drugs as a result of this harmonization. We subsequently demonstrated improved matching between a patient cohort and harmonized interpretations of potential clinical significance, observing an increase from an average of 33% per individual knowledgebase to 57% in aggregate. Our analyses illuminate the need for open, interoperable sharing of variant interpretation data. We also provide a freely available web interface (search.cancervariants.org) for exploring the harmonized interpretations from these six knowledgebases.